5:41 PM
 | 
Nov 08, 2012
 |  BC Extra  |  Company News

FDA accepts suvorexant NDA

Merck & Co. Inc. (NYSE:MRK) said FDA accepted for review an NDA for suvorexant...

Read the full 54 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >